SCHEMBL10189626

SCHEMBL10189626

COc1cc(-n2nncc2-c2ccc(SC)c(OP(=O)(O)O)c2)cc2c1OCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPSR1 Q6W5P4 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 3/20 0.38
HPGD P15428 3/20 0.35
MAPT P10636 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TP53 P04637 1/20 0.35
CA12 O43570 2/20 0.34
CA9 Q16790 2/20 0.34
FYN P06241 1/20 0.33
AHR P35869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14619287 0.92 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL413860 0.89 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL412015 0.86 CA12 (0.43) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL10189621 0.85 ACHE (0.37) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL408081 0.85 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL412031 0.84 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL411844 0.84 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL14376767 0.83 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL10189597 0.82 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP3A4
SCHEMBL408764 0.81 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2CYP3A4LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed
US-20100279410-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2010-11-04 US disclosed
US-7781462-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2010-08-24 US disclosed
US-20070238699-A1 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238699-A1 Compounds for the treatment of proliferative disorders RB1, MKI67, MAPRE1 ALDH1A1 1872/4885SMN1; SMN2 3188/4885NPSR1 1837/4885
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885SMN1; SMN2 3188/4885NPSR1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.